Industry Reports
Roche Group posts strong sales growth in the third quarter
Roche sales grew 4% to 33.7 billion Swiss francs thanks to strong demand for its cancer medicines and its clinical lab business. Uptake of the Group's recently launched cancer medicines Zelboraf, Erivedge and Perjeta has been positive. The...
Industry Reports
BIOGEN IDEC TO REPORT THIRD QUARTER 2012 FINANCIAL RESULTS ON OCTOBER 25, 2012
Biogen Idec Inc. today announced it will report third quarter 2012 financial results on Thursday, October 25, 2012, before the financial markets open. Following the release of the financials, the Company will host a live webcast...
Industry Reports
Interleukin Genetics Reports Second Quarter 2012 Financial Results
Interleukin Genetics, Inc. today announced financial and operational results for the second quarter ended June 30, 2012. Total revenue for the three months ended June 30, 2012 was $799,000, compared to $797,000 for the...
Industry Reports
Sanofi second-quarter and first-half sales 2012
In the second quarter of 2012, Sanofi generated net sales of €8,870 million, up 6.2% on a reported basis. Exchange rate movements had a positive effect of 5.8 percentage points reflecting the appreciation of the U.S. dollar and,...
Industry Reports
Pfizer reports second-quarter 2012 results
Pfizer Inc. reported financial results for second-quarter 2012. Second-quarter 2012 revenues were $15.1 billion, a decrease of 9% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of $977 million, or 6%, and the...
Industry Reports
Amgen’s second quarter 2012 revenues increased 13 percent to $4.5 billion
Amgen announced financial results for the second quarter of 2012. Key results for the quarter include: Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfolio; Amgen...
Industry Reports
Novartis second quarter results enhance future growth prospects
Group net sales reached USD 14.3 billion (-4%, +1% cc) in the second quarter, with growth from recently launched products more than offsetting the loss associated with the Diovan patent expiration. Currency had a negative impact of 5...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read